Ionetix

About

Leadership

  • 01-kevin-j-cameron

    Kevin J. Cameron

    Chairman & CEO

    Prior to joining Ionetix, Mr. Cameron served as President of Glass, Lewis & Co., a leading independent corporate governance research firm which he co-founded in 2003. Prior to Glass Lewis, he served as General Counsel at Moxi Digital, a technology venture founded by Microsoft co-founder Paul Allen. Mr. Cameron previously served as General Counsel at NorthPoint Communications, a publicly-traded broadband telecommunications company acquired by AT&T. Before NorthPoint, he was an attorney with the corporate law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington D.C. and served as a law clerk to the Hon. James L. Buckley of the United States Court of Appeals for the District of Columbia Circuit. Mr. Cameron has served on multiple private and public company boards, and earned a J.D. from the University of Chicago and a B.A.(hons) from McGill University. 
  • 02-phieu-phun

    Phieu Phun

    Chief Financial Officer

    Phieu Phun joined Ionetix from Vaxcyte, a developer of next-generation pneumococcal conjugate vaccines, where he was Executive Director and Head of Finance. Phieu has more than 20 years of experience in finance, corporate development and operations in healthcare industry. During his time at Vaxcyte, Phieu executed several financing transactions, including the company’s crossover financing, initial public offering and follow-on offering as well as provided strategic and operational leadership. Prior to Vaxcyte, Phieu served as Vice President and Head of Corporate Development for Proteus Digital Health. Phieu previously spent over 10 years at McKesson heading up M&A, business development and operations with P&L responsibility. Phieu began his career in investment banking at J.P. Morgan, Merrill Lynch and Lehman Brothers where he led and played key roles in a broad range of M&A and financing transactions valued in excess of $25 billion. 
  • 03-david-eve

    David Eve

    Chief Business Development Officer

    David Eve serves as Chief Business Development Officer at Ionetix, overseeing the Company’s business development and commercial strategy across its diagnostic and therapeutic isotope portfolio. He joined Ionetix in 2013, initially leading the company’s sales and nuclear cardiology business development efforts. Before assuming his current role, Mr. Eve served as Vice President of Medical Affairs, supporting clinical and scientific engagement with customers, key opinion leaders (KOLs), and partners.

    Prior to Ionetix, Mr. Eve was Vice President of Operations and Strategic Development at Soteria Imaging Services, LLC, a national leader in outpatient medical imaging. His previously roles included Vice President of Technical Services, Vice President of PET Operations and Director of Facility Operations. Mr. Eve earned his B.S. in Nuclear Medicine from Wheeling Jesuit University.

  • 04-xiaoyu-wu

    Xiaoyu Wu PhD

    Chief Technology Officer

    Dr. Xiaoyu Wu brings over 33 years of extensive experience in accelerator R&D in U.S. National laboratories, universities, and private industries. His involvement spans the design, development, manufacturing, and operation of superconducting cyclotrons, rapid cycling synchrotrons, and superconducting linacs. At present, Dr. Wu is leading the R&D effort on cyclotron-based alpha emitter Actinium-225 and Astatine-211 productions at Ionetix. Since joining Ionetix in 2015, he has actively participated in the R&D of the Ion-12SC compact superconducting isochronous cyclotron for medical radioisotope production. Additionally, Dr. Wu has made significant contributions to K230 and SC240 superconducting cyclotrons for proton cancer therapy specifically designed for Pronova Inc. and HFCIM. Before his tenure at Ionetix, Dr. Wu was a senior accelerator physicist at the National Superconducting Cyclotron Laboratory (NSCL) and the Facility for Rare Isotope Beams (FRIB) at Michigan State University (MSU). Following the completion of his Ph.D. in Accelerator Physics from MSU, he worked at the Superconducting Super Collider Laboratory (SSCL). Dr. Wu earned his bachelor’s and master’s Degrees from Tsinghua University. 
  • 05-jill-wilson

    Jill Wilson

    Vice President of Regulatory Affairs & Quality Assurance

    Jill Wilson joined Ionetix in 2018 and has played a pivotal role in advancing the company’s regulatory and quality infrastructure. She led Ionetix’s first FDA submission and was instrumental in establishing the organization’s Quality Assurance program. She currently serves as Vice President of Regulatory Affairs & Quality Assurance.

    Prior to joining Ionetix, Jill spent 17 years at SOFIE, where she held progressively senior leadership roles across operations, quality, and regulatory functions supporting PET and theranostics programs.

    Jill brings extensive expertise in lifecycle management, having authored and submitted multiple PET ANDAs and successfully guided them through FDA approval. She also has significant experience in regulatory compliance, having directly participated in and overseen more than 30 FDA inspections.

    She holds a Bachelor of Arts in Consumer Affairs from Montclair State University and maintains a Regulatory Affairs Certification (RAC).

  • 06-mark-leuschner

    Mark Leuschner, PhD

    VP of Nuclear and Radiation Sciences

    Mark Leuschner, PhD, serves as Vice President of Nuclear and Radiation Sciences at Ionetix. He joined Ionetix in 2012 as Vice President of Operations, a role he held for more than seven years before moving into his current position in 2020.

    Before joining Ionetix, Dr. Leuschner spent nearly six years at ProCure, first as Director of Physics Research and later as Director of Operations Research.

    Dr. Leuschner began his career in academia, holding physics research professorships at Indiana University Bloomington and the University of New Hampshire, following a postdoctoral appointment at Indiana University. He earned his PhD in Nuclear Physics from the University of New Hampshire and his BS in Physics from the University of Massachusetts Amherst.

  • 07-dominica-palacio

    Dominica Palacio

    Vice President of Administration

    Dominica Palacio joined Ionetix in 2018 and serves as Vice President of Administration, where she leads Human Resources and Information Technology functions that support the company’s growth and operational excellence.

    She has been instrumental in advancing organizational development initiatives and fostering a culture grounded in excellence, innovation, and collaboration.

    Dominica has successfully built and scaled a dynamic, inclusive workplace that attracts, develops, and retains top talent. In her role, she provides strategic leadership in aligning people strategies with business objectives to drive sustainable growth and enhance overall performance.

    With more than 25 years of experience spanning executive HR and technology-focused roles, Dominica integrates information systems, process optimization, and workforce strategy to improve efficiency and scalability across the organization.

    She holds a Bachelor of Science from Michigan State University and an MBA from Northwood University.

  • 08-paul-surdez

    Paul Surdez

    Head of Investor Relations

    Paul Surdez brings more than 25 years of investor relations and corporate communications leadership to Ionetix. His career spans multiple global public healthcare companies, including Catalent, LabCorp, and Covance, where he counseled the C-Suite on public disclosures, guidance, capital allocation, corporate governance, stakeholder communications, and M&A activity. He has been recognized numerous times in institutional investor surveys as a top investor relations officer. Paul holds an M.B.A. and B.S. from Rutgers Business School.